Research
The label rules written because of weight loss
Two drug classes carry a boxed warning that exists for one reason: they were being prescribed for obesity. The regulation says so in its own first sentence, and a third rule dates to 1941.
A regulation that explains its own motive
Most labeling regulations state a requirement and stop. A few explain why they exist, and those are the interesting ones.
Two sections of the drug labeling rules open by describing a marketing pattern rather than a chemical property.
Both say the same thing about a class of drugs. It has been promoted for, and continues to be dispensed and prescribed for, use in the treatment of obesity. Safety and effectiveness for that use have never been established.
The remedy in both cases is the same. A boxed warning at the beginning of the warnings section, with the text written into the regulation itself.
The thyroid rule, and the sentence at its center
The first covers drugs with thyroid hormone activity for human use. Without the required boxed warning, they are misbranded within the meaning of the statute.
The warning text is set out in the regulation. It begins by acknowledging the practice: drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity.
Then the finding. "In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction."
And the consequence of going higher. "Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects."
That is a complete argument in three sentences. Normal doses do not work for this. Bigger doses are dangerous. Combining them with stimulants is worse.
The same shape, applied to a heart drug
The second section covers digitalis and related cardiotonic drugs for human use in oral dosage forms, and its opening sentence is nearly identical to the thyroid one.
Its boxed warning is blunter. Digitalis alone or with other drugs has been used in the treatment of obesity, and the regulation states that "This use of digoxin or other digitalis glycosides is unwarranted."
It then gives the reason: "Moreover, since they may cause potentially fatal arrhythmias or other adverse effects, the use of these drugs in the treatment of obesity is dangerous."
The section carves out one category. It does not apply to digoxin products for oral use, which are governed elsewhere.
Why these two rules are worth a peptide buyer's attention
Neither section is about peptides. Both are about something structurally familiar.
A drug class with a real, narrow medical purpose gets adopted for weight loss. The adoption spreads through prescribing and promotion rather than through evidence. The regulatory response is not to ban the drug but to force a sentence onto its label.
The label sentence in each case is a statement about an absence: safety and effectiveness for that use have never been established.
That is the same sentence shape a careful reader should be looking for whenever a substance with one recognized use is being sold for a different, more popular one.
The 1941 notice about gland preparations
A third section in the same subpart is much older and covers a category that reads as an ancestor of parts of this market.
It records a notice dated December 4, 1941. In it the agency expressed the opinion that preparations of inert glandular materials intended for medicinal use should carry a particular label statement. That statement was of the material fact that there is no scientific evidence that the articles contain any therapeutic or physiologically active constituents.
The regulation then defines its term. Inert glandular materials means "preparations incapable of exerting an action or effect of some significant or measurable benefit in one way or another". The regulation then names the arenas: diagnosis, cure, mitigation, treatment or prevention of disease, or affecting the structure or any function of the body.
Numerous such preparations were subsequently marketed with disclaimers of the type suggested, and the section records that too.
The trap the notice closed
The gland preparations section then follows a chain of reasoning that is worth tracing, because it closes a route people still try.
Manufacturers had been using the exemption that lets a prescription drug omit directions for use when its label bears the prescription legend. That exemption comes with a condition: the labeling must carry information for the drug's use by practitioners licensed to administer it.
The section states the obvious problem in a single word. "Obviously, information adequate for the use of an inert glandular preparation is not available to practitioners licensed by law."
So the exemption cannot be used. And the department's stated opinion is that these materials may not be exempted from the requirement to bear adequate directions for use.
Which forces the labeling to include representations about the conditions the article is intended for, or the structure or function it is intended to affect. The section then draws its conclusion. Since any such representations would be false or misleading, the articles will be considered misbranded if distributed for use as drugs.
And the line about injections
The gland preparations section closes with a paragraph specific to route of administration.
For drugs intended for parenteral administration there is no exemption at all from the requirement that labeling bear adequate directions for use.
Inert glandular materials for parenteral use are therefore subject to the same comment as those intended for oral administration.
The structural point survives the age of the document. An injectable does not get the labeling relief that an oral prescription product can claim.
A potency unit that was ruled misleading
One more section in this group deals with how potency is stated, and it is a useful example of a claim that is wrong in its units rather than its numbers.
Some preparations made wholly or partly from estradiol had been labeled in international units, or in international units of estrone activity. The international unit for the estrus-producing hormone was established at a 1932 conference and defined against a standard hormone found in urine.
The conference itself declined to recommend measuring other forms in units of estrone, because the ratio between their activity and estrone's varies with the method and the test animal.
The regulation draws the conclusion. There is no international unit for measuring the activity of estradiol. There is no accepted relationship between its activity and that of estrone, in test animals or in humans. Declaring potency that way is therefore considered misleading. Declaring the content by weight is considered appropriate.
A companion section deals with naming rather than potency, recording that a substance formerly designated alpha estradiol should no longer be referred to that way in drug labeling.
What to carry away
These are old rules about drug classes that are not peptides, and nothing here says anything about any peptide, seller or product.
What they supply is a set of reasoning patterns a reader can reuse. A promotional use can be widespread and still unestablished, and a regulator can respond by requiring the label to say so.
A dose that is safe for one purpose is not automatically safe at the larger dose a different purpose would require. Both boxed warnings turn on exactly that.
A potency figure can be misleading because of the unit it is expressed in, even when the number is accurate. And a preparation described by its biological source is not thereby described by any activity.
Key takeaways
- Two drug classes carry a required boxed warning specifically because they were used for obesity.
- Both regulations state that safety and effectiveness for weight loss have never been established.
- The thyroid warning says ordinary doses are ineffective for weight reduction and larger ones may be life-threatening.
- The digitalis warning calls that use unwarranted and dangerous, and excludes oral digoxin products.
- A 1941 notice required gland preparations to disclose the absence of evidence of active constituents.
- Injectables get no exemption from the requirement to bear adequate directions for use.
Frequently asked questions
Why do thyroid drugs carry a warning about obesity?
Because the regulation requires it. The section records that drugs with thyroid hormone activity have been promoted for, and continue to be dispensed and prescribed for, the treatment of obesity. Safety and effectiveness for that use have never been established. Without the boxed warning the regulation prints, such drugs are misbranded within the meaning of the statute.
What does the thyroid boxed warning actually say?
That these drugs, alone or with other therapeutic agents, have been used for treating obesity. That in euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. And that larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given with sympathomimetic amines such as those used for their anorectic effects.
What is an "inert glandular material" in the labeling rules?
The regulation defines the term as preparations incapable of exerting an action or effect of some significant or measurable benefit in one way or another. That covers the diagnosis, cure, mitigation, treatment or prevention of disease, and affecting the structure or any function of the body. The section traces back to a notice dated December 4, 1941.
Can an injectable claim the same labeling exemption as an oral prescription drug?
Not under the gland preparations section. It states that for drugs intended for parenteral administration there is no exemption from the requirement that their labeling bear adequate directions for use. It applies the same reasoning to parenteral inert glandular materials as to oral ones.
Do these rules apply to peptides?
No. They apply to drugs with thyroid hormone activity, to digitalis and related cardiotonic drugs in oral dosage forms, to inert glandular preparations, and to estradiol labeling. Nothing here states or implies anything about any peptide, seller or product. What transfers is the reasoning: a widespread promotional use can be entirely unestablished, and a regulator can require the label to say so.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- 21 CFR 201.300, Notice to manufacturers, packers, and distributors of glandular preparations — Electronic Code of Federal Regulations, title 21, August 2026
- 21 CFR 201.301, Notice to manufacturers, packers, and distributors of estrogenic hormone preparations — Electronic Code of Federal Regulations, title 21, August 2026
- 21 CFR 201.313, Estradiol labeling — Electronic Code of Federal Regulations, title 21, August 2026
- 21 CFR 201.316, Drugs with thyroid hormone activity for human use; required warning — Electronic Code of Federal Regulations, title 21, May 1978
- 21 CFR 201.317, Digitalis and related cardiotonic drugs for human use in oral dosage forms; required warning — Electronic Code of Federal Regulations, title 21, November 2020